Literature DB >> 19047275

Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.

Carmen P Castaneda, Nancy A Brandenburg, Robert Bwire, Graham H Burton, Jerome B Zeldis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19047275     DOI： 10.1200/JCO.2008.20.3737

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.

Authors:  Satoshi Morishige; Marina Nishi; Hiroshi Saruta; Fumiko Arakawa; Yoshitaka Yamasaki; Shuki Oya; Takayuki Nakamura; Ritsuko Seki; Maki Yamaguchi; Kazutoshi Aoyama; Fumihiko Mouri; Koichi Osaki; Koichi Ohshima; Koji Nagafuji
Journal:  Int J Hematol       Date:  2019-05-31       Impact factor: 2.490

2.  Highly Probable Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Lenalidomide.

Authors:  Anusha Shanbhag; E Ryan Pritchard; Kshitij Chatterjee; Drayton A Hammond
Journal:  Hosp Pharm       Date:  2017-07-18

3.  Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.

Authors:  Pascale Olivier-Abbal; Anne-Charlotte Teisseyre; Jean-Louis Montastruc
Journal:  Med Oncol       Date:  2013-09-28       Impact factor: 3.064

4.  Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome.

Authors:  Yun-Jin Jeung; Jin-Young Lee; Mi-Jung Oh; Dong-Chull Choi; Byung-Jae Lee
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

5.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

6.  Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.

Authors:  A Siniscalchi; A Tendas; L Morino; T Dentamaro; A De Bellis; A Perrotti; P de Fabritiis; P Musto; T Caravita
Journal:  Support Care Cancer       Date:  2012-05-05       Impact factor: 3.603

Review 7.  Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies.

Authors:  Susan Blumel; Jackie Broadway-Duren
Journal:  J Adv Pract Oncol       Date:  2014 Jul-Aug

Review 8.  Cutaneous complications of molecular targeted therapy used in oncology.

Authors:  I Lupu; N Voiculescu; N Bacalbasa; I Cojocaru; V Vrancian; C Giurcaneanu
Journal:  J Med Life       Date:  2016 Jan-Mar

Review 9.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

Review 10.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.